Debating the Food Debate, Two Views (2)

It's understandable that The Scientist's coverage of the GMO [genetically modified organism] debate focuses on the science of crop technology, and understandable if most of your readers favor continued research and development of GMOs. However, I should hope your editors, reporters, and readers also understand that technology is just one dimension of the controversy. For some GMO critics, social and political concerns outweigh arguments over bioengineered crops' safety to humans and the natural

Written byDerek Maurer
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

It's understandable that The Scientist's coverage of the GMO [genetically modified organism] debate focuses on the science of crop technology, and understandable if most of your readers favor continued research and development of GMOs. However, I should hope your editors, reporters, and readers also understand that technology is just one dimension of the controversy. For some GMO critics, social and political concerns outweigh arguments over bioengineered crops' safety to humans and the natural environment.

By framing practically every one of your reports in terms of the safety issue, The Scientist, like most mainstream news organizations, risks portraying GMO critics merely as anti-science. An article quoting three sources who weigh in on the side of GMO benefits, plus a fourth who expresses some mild caution, [can] leave the impression that anyone who opposes bioengineered crops must be willfully ignorant or ideologically motivated. Left unexplored is the question at the core of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies